Abstract: The present application refers to a medicinally active compound of formula (I) and its possible use as anti-inflammatory agent. Further, the present application refers to a method for the preparation of the compound of formula (I) as well as to a pharmaceutical composition comprising a compound of formula (I).

Abstract: A composition, especially for treatment of aged and/or stressed skin, the composition containing, in addition to water, at least one substance that forms lamellar structures with water. The composition further contains S-adenosylmethionine and/or at least one compound that contains a functional group of the general formula —CH2—N?—(CH3)3. The lamellar structure has a layer structure in which an upper layer of the substance is aligned with a lower layer, the hydrophilic groups of the substance each point outwards, and the lipophilic groups of the substance are aligned inwards with one another. The lamellar structure is surrounded by a hydrophilic medium, preferably water.

Abstract: A cosmetic composition, especially for use on aged and/or stressed skin is described, whereby apart from water at least one substance forming lamellar structures with water is present in the composition. The composition further contains a) at least one compound which has at least one functional group of the general formula I —CH2—N?—(CH3)3??(formula I) b) and/or at least one metabolite of this compound, c) and/or S-adenosylmethionine.

Abstract: A composition, especially for treatment of aged and/or stressed skin, the composition containing, in addition to water, at least one substance that forms lamellar structures with water. The composition further contains S-adenosylmethionine and/or at least one compound that contains a functional group of the general formula —CH2—N?—(CH3)3. The lamellar structure has a layer structure in which an upper layer of the substance is aligned with a lower layer, the hydrophilic groups of the substance each point outwards, and the lipophilic groups of the substance are aligned inwards with one another. The lamellar structure is surrounded by a hydrophilic medium, preferably water.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one active compound having cytostatic activity, at least one biological electron acceptor and customary pharmaceutical additives, and to its use for the treatment of tumor diseases, in particular for the treatment of cancer.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one active compound having cytostatic activity, at least one biological electron acceptor and customary pharmaceutical additives, and to its use for the treatment of tumor diseases, in particular for the treatment of cancer.

Abstract: A method for the stabilization of a phospholipidic composition as well as a method for the production of a stabilized phospholipidic composition comprising at least one phospholipide as well as a stabilizer are described, whereby in the claimed methods at least one phospholipide is mixed with a stabilizer on the basis of phytic acid, of a salt of the phytic acid and/or of a phytic acid derivative.

Abstract: A method for the stabilization of a phospholipidic composition as well as a method for the production of a stabilized phospholipidic composition comprising at least one phospholipide as well as a stabilizer are described, whereby in the claimed methods at least one phospholipide is mixed with a stabilizer on the basis of phytic acid, of a salt of the phytic acid and/or of a phytic acid derivative.

Abstract: A phospholipidic composition provides resistance against rancidity and the development of undesirable odors. The composition includes at least one phospholipid and a stabilizer. The stabilizer is ground parts and/or an extract of a grain. The composition is prepared by simple and reliable methods of production.

Abstract: A method for the stabilization of a phospholipidic composition as well as a method for the production of a stabilized phospholipidic composition comprising at least one phospholipide as well as a stabilizer are described, whereby in the claimed methods at least one phospholipide is mixed with a stabilizer on the basis of phytic acid, of a salt of the phytic acid and/or of a phytic acid derivative.

Abstract: An alcoholic, aqueous gel-like phospholipid composition is disclosed which contains, as alcohols, ethanol, 1-propanol or 2-propanol, which is characterized in that this composition is a liposomal gel composed of 15.00 to 30.00 parts by weight of a phospholipid concentrate, 14.00 to 20.00 parts by weight of alcohol and 50 to 71.00 parts by weight of an aqueous solution as the remainder. The use of this phospholipid composition for the preparation of liposomal solutions by dilution with a solution and topical preparations which contain these solutions are additionally disclosed.

Abstract: An alcoholic, aqueous gel-like phospholipid composition is disclosed which contains, as alcohols, ethanol, 1-propanol or 2-propanol, which is characterized in that this composition is a liposomal gel composed of 15.00 to 30.00 parts by weight of a phospholipid concentrate, 14.00 to 20.00 parts by weight of alcohol and 50 to 71.00 parts by weight of an aqueous solution as the remainder. The use of this phospholipid composition for the preparation of liposomal solutions by dilution with a solution and topical preparations which contain these solutions are additionally disclosed.

Abstract: A method of inhibiting oxidation of products containing unsaturated fatty acids and their derivatives comprises treating the unsaturated fatty acids and their derivatives with N-acylphosphatidylethanolamines. Preferred N-acylphosphatidylethanolamines are N-acetylphosphatidylethanolamine and N-oleoylphosphatidylethanolamine.

Abstract: The invention is related to the use of certain water-soluble compounds known as such and having the FormulaR.sup.1 --CO--NH--R.sup.2for the modulation of membrane dependent metabolism processes within living cells, in particular with relation to transport phenomena and cell procedures which are induced or influenced by active agents supplied from outside the cell, products containing these substances for the above described uses and processes using these products.

Abstract: Liquid phospholipid-containing products in an aqueous medium which contains 5-80% by weight of phospholipids and 3-10% by weight of one or more compounds of the general formulaRO--A--NR.sub.1 R.sub.2 R.sub.3their preparation and their use, for example as additives for improving plant treatment agents.

Abstract: Pharmaceutical preparation containing phospholipids for the therapeutic treatment of rheumatic diseases which contain in addition to the antiphlogistically acting oxicam derivatives of the general formula ##STR1## special 1,2-diacyl-glycero-3-phosphocholines wherein 75-86% by weight of the acyl radicals are unsaturated fatty acid radicals, and the preparation thereof.

Abstract: Pharmaceutical formulations for the treatment of gastrointestinal disorders, which contain as the active component an effective gastrointestinal disorder alleviating amount of a 1,2-diacylglycero-3-phosphocholine in which 75-86% by weight of the acyl radicals are unsaturated fatty acid radicals having a chain length of 16, 18 or 20 carbon atoms. The mixtures of fatty acid radicals in the acyl groups in the 1- and 2-positions preferably have different compositions. The formulations can also contain other active compounds, in particular those which display injurious gastrointestinal side effects.

Abstract: Phospholipid concentrates from natural or synthetic phospholipids and physiologically acceptable organic solvents and further additives of the following composition:20-60 wght. % phospholipids0-23 wght. % glycerin5-62.5 wght. % organic solvent0-30 wght. % co-emulsifier0-35 wght. % dissolving intermediary0-15 wght. % water0-15 wght. % vegetable oil or neutral oilThe phospholipids are a mixture of phosphatidyl choline, phosphatidyl ethanol amine, N-acetyl phosphatidyl ethanol amine, and other phosphatides, the concentrates perferably containing a mixture of 10-50 wght. % phosphatidyl choline, 10-30 wght. % phosphatidyl diethanol amine, 10-30 wght. % N-acylphosphatidyl ethanol amine, and 3-10 wght. % other phosphatides, in relation to the total quantity of phospholipids. The phospholipid concentrates are particularly suitable as auxiliary agents in the production and application of spray mixtures containing plant protectants.

Abstract: New foliage fertilizers containing one or more macronutrients and/or one or more micronutrients as well as 10 to 50% by weight (referred to total nutrients) of one or more phospholipids.

Abstract: Liquid, active substance formulations containing an active substance insoluble or poorly soluble in water, or a mixture, a phospholipid, a special co-emulsifier (glycerinester in which the 1 or 2 OH groups have been esterized with hydrocarbon atoms of 8-16, preferably 8-10, C atoms by means of fatty acids and the 3 or remaining OH group of the glycerin body has been etherized with polyethyleneglycol, specifically, with 6-30, preferably 6-15 ethyleneoxide units) and a liquid carrier, the molar ratio of phospholipid to co-emulsifier being from 1:1 to 1:4, and the formulations being such that when added to water they form a transparent liquid system in the form of a microemulsion, with a degree of fineness of 10-200 nm in the lipid phase.